Literature DB >> 23798573

Metastasin S100A4 is a mediator of sex hormone-dependent formation of the cortical bone.

Malin C Erlandsson1, Li Bian, Ing-Marie Jonsson, Karin M Andersson, Maria I Bokarewa.   

Abstract

S100A4 is a Ca-binding protein participating in regulation of cell growth, survival, and motility. Here we studied the role of S100A4 protein in sex hormone-regulated bone formation. Bone mineral density in the trabecular and cortical compartments was evaluated in female S100A4 knockout (KO), in matched wild-type (WT) counterparts, and in WT mice treated with lentiviral small hairpin RNA construct inhibiting the S100A4 gene transcription or with a nontargeting construct, by peripheral quantitative computed tomography. The effect of sex hormones on bone was measured 5 weeks after ovariectomy (OVX) and/or dehydroepiadrosterone treatment. S100A4KO had an excessive trabecular and cortical bone formation compared with the age- and sex-matched WT mice. S100A4KO had an increased periosteal circumference (P = .001), cortical thickness (P = .056), and cortical area (P = .003), which predicted 20% higher bone strength in S100A4KO (P = .013). WT mice treated with small hairpin RNA-S100A4 showed an increase of the cortical bone parameters in a fashion identical with S100A4KO mice, indicating the key role of S100A4 in the changed bone formation. S100A4KO mice had higher serum levels of osteocalcin and a higher number of osteocalcin-positive osteoblasts under the periosteum. OVX-S100A4 resulted in the loss of the cortical bone supported by high CTX-I levels, whereas no such changes were observed in OVX-WT mice. S100A4KO mice resisted the dehydroepiadrosterone -induced bone formation observed in the WT counterparts. Our study indicates that S100A4 is a regulator of bone formation, which inhibits bone excess in the estrogen-sufficient mice and prevents the cortical bone loss in the estrogen-deprived mice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23798573      PMCID: PMC5427947          DOI: 10.1210/me.2012-1398

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  47 in total

1.  Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction.

Authors:  M Grigorian; S Andresen; E Tulchinsky; M Kriajevska; C Carlberg; C Kruse; M Cohn; N Ambartsumian; A Christensen; G Selivanova; E Lukanidin
Journal:  J Biol Chem       Date:  2001-03-05       Impact factor: 5.157

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 3.  S100A4 and metastasis: a small actor playing many roles.

Authors:  Kjetil Boye; Gunhild M Maelandsmo
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

4.  DHEA in elderly women and DHEA or testosterone in elderly men.

Authors:  K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Ketan Dhatariya; Kevin R Short; Ajay Nehra; Janet L Vittone; George G Klee; Ananda Basu; Rita Basu; Claudio Cobelli; Gianna Toffolo; Chiara Dalla Man; Donald J Tindall; L Joseph Melton; Glenn E Smith; Sundeep Khosla; Michael D Jensen
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

5.  S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme.

Authors:  K Bjørnland; J O Winberg; O T Odegaard; E Hovig; T Loennechen; A O Aasen; O Fodstad; G M Maelandsmo
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

6.  Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice.

Authors:  C Du; M W Khalil; S Sriram
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

7.  S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases.

Authors:  L Senolt; M Grigorian; E Lukanidin; B Simmen; B A Michel; K Pavelka; R E Gay; S Gay; M Neidhart
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

8.  The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer.

Authors:  Ulrike Stein; Franziska Arlt; Wolfgang Walther; Janice Smith; Todd Waldman; Erik D Harris; Susan D Mertins; Claus W Heizmann; David Allard; Walter Birchmeier; Peter M Schlag; Robert H Shoemaker
Journal:  Gastroenterology       Date:  2006-08-22       Impact factor: 22.682

9.  Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis.

Authors:  Gisle Berge; Solveig Pettersen; Ida Grotterød; Ingrid J Bettum; Kjetil Boye; Gunhild M Mælandsmo
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

10.  The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.

Authors:  S Bord; D C Ireland; S R Beavan; J E Compston
Journal:  Bone       Date:  2003-02       Impact factor: 4.398

View more
  4 in total

1.  Insulin Receptor deletion in S100a4-lineage cells accelerates age-related bone loss.

Authors:  Valentina Studentsova; Emma Knapp; Alayna E Loiselle
Journal:  Bone Rep       Date:  2019-02-05

2.  Altered Levels of mRNAs for Calcium-Binding/Associated Proteins, Annexin A1, S100A4, and TMEM64, in Peripheral Blood Mononuclear Cells Are Associated with Osteoporosis.

Authors:  Ayed A Dera; Lakshminarayan Ranganath; Roger Barraclough; Sobhan Vinjamuri; Sandra Hamill; Abdullah Y Mandourah; Dong L Barraclough
Journal:  Dis Markers       Date:  2019-11-11       Impact factor: 3.434

3.  S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity.

Authors:  Barbora Šumová; Lucie Andrés Cerezo; Hana Hulejová; Klára Prajzlerová; Michal Tomčík; Kristýna Bubová; Jan Štěpán; Mária Filková; Tereza Kropáčková; Mariam Grigorian; Karel Pavelka; Jiří Vencovský; Ladislav Šenolt
Journal:  BMC Rheumatol       Date:  2020-01-31

4.  Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor.

Authors:  Arsheed A Ganaie; Adrian P Mansini; Tabish Hussain; Arpit Rao; Hifzur R Siddique; Ashraf Shabaneh; Marina G Ferrari; Paari Murugan; Jörg Klingelhöfer; Jinhua Wang; Noona Ambartsumian; Christopher A Warlick; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Cancer Ther       Date:  2020-09-30       Impact factor: 6.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.